HC Wainwright Has Lowered Expectations for Zura Bio (NASDAQ:ZURA) Stock Price

Zura Bio (NASDAQ:ZURA) had its price objective trimmed by HC Wainwright from $5.00 to $3.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other research analysts have also recently issued reports on the stock. Chardan Capital dropped their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Oppenheimer reaffirmed an “outperform” rating and issued a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $14.67.

Zura Bio Stock Performance

ZURA stock opened at $1.03 on Thursday. The stock has a market capitalization of $67.25 million, a PE ratio of -1.94 and a beta of 0.08. The company has a fifty day moving average of $1.40 and a 200-day moving average of $2.64. Zura Bio has a one year low of $0.97 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter. Equities analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its position in Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after acquiring an additional 7,828 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock worth $58,000 after acquiring an additional 9,379 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares during the period. Rhumbline Advisers raised its position in shares of Zura Bio by 37.3% in the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after buying an additional 10,231 shares during the period. Finally, American Century Companies Inc. acquired a new position in Zura Bio in the fourth quarter valued at $27,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.